Gossamer Bio vs Roivant Sciences
GOSS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GOSS and ROIV compare
Roivant Sciences is the larger company, worth 5.2 times as much as Gossamer Bio ($28.0B against $5.4B).
Gossamer Bio grew revenue faster over the last twelve months (32.4% versus −67.6% for Roivant Sciences).
Gossamer Bio keeps more of each dollar of sales as profit, with a net margin of −235% compared with −3535% at Roivant Sciences.
Roivant Sciences scores higher on the StockData Score (7 against 1 for Gossamer Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GOSS | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $5.4B | $28.0B |
| Share price | $11.04 | $38.71 |
| Change, 1 year | −94.9% | 90.8% |
| Change, 5 years | −98.7% | 453% |
| Beta (5Y) | 2.33 | 0.42 |
| Employees | 161 | 721 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 101× (better) | 3712× |
| P/B | – | 6.6× |
| FCF yield | −3.0% | −2.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 32.4% (better) | −67.6% |
| Revenue growth, 5Y average | – | −19.1% |
| Profitability | ||
| Operating margin | −312% (better) | −7915% |
| Net margin | −235% (better) | −3535% |
| FCF margin | −305% (better) | −10901% |
| Return on equity | – | −6.2% |
| Return on invested capital | – | −407% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −15.2× | – |
| Current ratio | 0.53 | 16.72 (better) |
| Altman Z-score | −15.26 | 44.02 (better) |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.98% | 78.1% |
| Held by insiders | 2.8% | 13.9% |
| Insider net buying, 12 months | – | −$798M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 0.28% | 7.3% |
Go deeper
- GOSS stock overview
- GOSS income statement
- GOSS valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.